| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
29,990,000 |
| Market
Cap: |
2.85(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.062 - $1.22 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Atreca is a clinical-stage biopharmaceutical company utilizing its platform to discover and develop antibody-based immunotherapeutics to treat a range of solid tumor types. Co.'s primary product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. Co. owns worldwide rights to ATRC-101.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
1 |
1 |
1 |
1 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
20,788 |
20,788 |
353,058 |
410,690 |
| Total Sell Value |
$1,455 |
$1,455 |
$144,635 |
$250,581 |
| Total People Sold |
1 |
1 |
6 |
6 |
| Total Sell Transactions |
1 |
1 |
9 |
14 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Robinson William Hewitt |
Director |
– • – |
2020-06-15 |
4 |
AS |
$17.48 |
$92,728 |
D/D |
(5,000) |
424,861 |
|
-26% |
|
| Serafini Tito |
Chief Strategy Officer |
• • – |
2020-06-11 |
4 |
AS |
$16.35 |
$164,686 |
I/I |
(10,000) |
445,920 |
|
-11% |
|
| Greenberg Norman Michael |
Chief Scientific Officer |
• – – |
2020-06-01 |
4 |
AS |
$18.38 |
$275,760 |
D/D |
(15,000) |
0 |
|
-13% |
|
| Greenberg Norman Michael |
Chief Scientific Officer |
• – – |
2020-06-01 |
4 |
OE |
$4.56 |
$68,400 |
D/D |
15,000 |
15,000 |
|
- |
|
| Serafini Tito |
Chief Strategy Officer |
• • – |
2020-05-28 |
4 |
S |
$20.01 |
$14,004 |
I/I |
(700) |
455,920 |
|
20% |
|
| Robinson William Hewitt |
Director |
– • – |
2020-05-28 |
4 |
AS |
$20.01 |
$12,003 |
D/D |
(600) |
429,861 |
|
-20% |
|
| Serafini Tito |
Chief Strategy Officer |
• • – |
2020-05-27 |
4 |
AS |
$20.00 |
$2,000 |
I/I |
(100) |
456,620 |
|
-19% |
|
| Serafini Tito |
Chief Strategy Officer |
• • – |
2020-05-26 |
4 |
AS |
$20.00 |
$4,000 |
I/I |
(200) |
456,720 |
|
-22% |
|
| Robinson William Hewitt |
Director |
– • – |
2020-05-26 |
4 |
AS |
$20.00 |
$7,740 |
D/D |
(387) |
430,461 |
|
-22% |
|
| Robinson William Hewitt |
Director |
– • – |
2020-05-18 |
4 |
AS |
$20.00 |
$32,003 |
D/D |
(1,600) |
430,848 |
|
-20% |
|
| Serafini Tito |
Chief Strategy Officer |
• • – |
2020-05-18 |
4 |
AS |
$20.00 |
$34,004 |
I/I |
(1,700) |
456,920 |
|
-20% |
|
| Robinson William Hewitt |
Director |
– • – |
2020-05-15 |
4 |
AS |
$20.00 |
$42,000 |
D/D |
(2,100) |
432,448 |
|
-24% |
|
| Serafini Tito |
Chief Strategy Officer |
• • – |
2020-05-15 |
4 |
AS |
$20.00 |
$44,000 |
I/I |
(2,200) |
458,620 |
|
-24% |
|
| Robinson William Hewitt |
Director |
– • – |
2020-05-13 |
4 |
AS |
$16.80 |
$84,105 |
D/D |
(5,000) |
434,548 |
|
-26% |
|
| Serafini Tito |
Chief Strategy Officer |
• • – |
2020-05-11 |
4 |
AS |
$17.64 |
$180,025 |
I/I |
(10,000) |
460,820 |
|
-25% |
|
| Greenberg Norman Michael |
Chief Scientific Officer |
• – – |
2020-05-07 |
4 |
AS |
$18.00 |
$90,000 |
D/D |
(5,000) |
0 |
|
-16% |
|
| Greenberg Norman Michael |
Chief Scientific Officer |
• – – |
2020-05-07 |
4 |
OE |
$4.56 |
$22,800 |
D/D |
5,000 |
5,000 |
|
- |
|
| Greenberg Norman Michael |
Chief Scientific Officer |
• – – |
2020-05-01 |
4 |
AS |
$15.03 |
$150,276 |
D/D |
(10,000) |
0 |
|
-22% |
|
| Greenberg Norman Michael |
Chief Scientific Officer |
• – – |
2020-05-01 |
4 |
OE |
$4.56 |
$45,600 |
D/D |
10,000 |
10,000 |
|
- |
|
| Serafini Tito |
Chief Strategy Officer |
• • – |
2020-04-16 |
4 |
AS |
$15.75 |
$162,761 |
I/I |
(10,000) |
470,820 |
|
-16% |
|
| Robinson William Hewitt |
Director |
– • – |
2020-04-16 |
4 |
AS |
$15.75 |
$81,271 |
D/D |
(5,000) |
439,548 |
|
-16% |
|
| Greenberg Norman Michael |
Chief Scientific Officer |
• – – |
2020-04-14 |
4 |
AS |
$18.00 |
$90,000 |
D/D |
(5,000) |
0 |
|
-7% |
|
| Greenberg Norman Michael |
Chief Scientific Officer |
• – – |
2020-04-14 |
4 |
OE |
$4.56 |
$22,800 |
D/D |
5,000 |
5,000 |
|
- |
|
| Greenberg Norman Michael |
Chief Scientific Officer |
• – – |
2020-04-08 |
4 |
AS |
$15.01 |
$120,101 |
D/D |
(8,000) |
0 |
|
-6% |
|
| Greenberg Norman Michael |
Chief Scientific Officer |
• – – |
2020-04-08 |
4 |
OE |
$4.56 |
$36,480 |
D/D |
8,000 |
8,000 |
|
- |
|
132 Records found
|
|
Page 4 of 6 |
|
|
